InvIOs GmbH | WebDisclosure

Basculer en Français

8201	Companies
109005	Keywords
51275	Articles
60079	Press releases

Home
Companies
InvIOs GmbH

BRIEF

published on 10/15/2024 at 10:35, 19 days 2 hours ago

InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations

Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF

published on 10/15/2024 at 10:35, 19 days 2 hours ago

InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie

Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE

published on 10/15/2024 at 10:30, 19 days 2 hours ago

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute

Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF

published on 07/17/2024 at 10:05, 3 months 17 days ago

InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma

Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
BRIEF

published on 07/17/2024 at 10:05, 3 months 17 days ago

InvIOs sélectionne le candidat principal INV501 pour des études IND-habilitantes sur le glioblastome et le mélanome

Thérapie Contre Le Cancer Etudes Précliniques Mélanome INV501 Glioblastome
PRESS RELEASE

published on 07/17/2024 at 10:00, 3 months 17 days ago

invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma. The compound shows strong activation of tumor-specific T cells in preclinical testing

Melanoma IND-enabling Studies INV501 Glioblastoma InvIOs
PRESS RELEASE

published on 11/09/2023 at 11:30, 11 months 24 days ago

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
PRESS RELEASE

published on 09/05/2023 at 09:00, 1 year 1 month ago

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
PRESS RELEASE

published on 06/19/2023 at 14:30, 1 year 4 months ago

invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
PRESS RELEASE

published on 04/18/2023 at 15:00, 1 year 6 months ago

invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023

Accesswire

Published on 11/03/2024 at 00:45, 12 hours 26 minutes ago

Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
Published on 11/02/2024 at 19:15, 17 hours 56 minutes ago

Hank Payments Announces Closing of Financing and Settlements
Published on 11/02/2024 at 16:10, 21 hours 1 minute ago

Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/02/2024 at 14:30, 22 hours 41 minutes ago

Spa Sciences Health Introduces Revolutionary Nasal Irrigation System at CVS
Published on 11/02/2024 at 00:48, 1 day 12 hours ago

OneSoft Solutions Inc. Announces the Completion of Its Acquisition by Irth Solutions LLC, a Blackstone Portfolio Company

View all ACCESSWIRE

EQS Group

Published on 11/01/2024 at 21:31, 1 day 15 hours ago

Original-Research: Telefonica Deutschland Holding AG (von First Berlin Equity Research GmbH): Buy
Published on 11/01/2024 at 18:18, 1 day 18 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/01/2024 at 17:47, 1 day 19 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/01/2024 at 17:10, 1 day 20 hours ago

EQS-Adhoc: fox e-mobility AG: provisional debt restructuring moratorium of Fox Automotive Switzerland AG
Published on 11/01/2024 at 16:00, 1 day 21 hours ago

Total Voting Rights

Les Echos

Published on 10/31/2024 at 20:26, 2 days 16 hours ago

I.CERAM - Résultat du 1er semestre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Déclaration hebdomadaire d'opérations effectuées du 28 au 31 octobre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Disclosure of transactions in own shares on October 28 to October 31, 2024
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2024 : +3%
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION: THIRD QUARTER 2024 TURNOVER UP 3%

View all LES ECHOS COMFI WIRE